thiotepa has been researched along with Anemia, Refractory, with Excess of Blasts in 2 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Anemia, Refractory, with Excess of Blasts: Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 9.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 5.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| " In order to decrease nonrelapse mortality, and enhance the graft-versus-tumor effect, a program was designed in which a reduced conditioning with thiotepa, fludarabine, and cyclophosphamide was associated with programmed reinfusions of donor lymphocytes for patients without graft-versus-host disease (GVHD), not achieving clinical and molecular remission after transplantation." | 3.71 | Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. ( Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bibawi, S | 1 |
| Abi-Said, D | 1 |
| Fayad, L | 1 |
| Anderlini, P | 1 |
| Ueno, NT | 1 |
| Mehra, R | 1 |
| Khouri, I | 1 |
| Giralt, S | 1 |
| Gajewski, J | 1 |
| Donato, M | 1 |
| Claxton, D | 1 |
| Braunschweig, I | 1 |
| van Besien, K | 1 |
| Andreeff, M | 1 |
| Andersson, BS | 1 |
| Estey, EH | 1 |
| Champlin, R | 1 |
| Przepiorka, D | 1 |
| Corradini, P | 1 |
| Tarella, C | 1 |
| Olivieri, A | 1 |
| Gianni, AM | 1 |
| Voena, C | 1 |
| Zallio, F | 1 |
| Ladetto, M | 1 |
| Falda, M | 1 |
| Lucesole, M | 1 |
| Dodero, A | 1 |
| Ciceri, F | 1 |
| Benedetti, F | 1 |
| Rambaldi, A | 1 |
| Sajeva, MR | 1 |
| Tresoldi, M | 1 |
| Pileri, A | 1 |
| Bordignon, C | 1 |
| Bregni, M | 1 |
1 trial available for thiotepa and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Bon | 2001 |
1 other study available for thiotepa and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graf | 2002 |